Sam Fazeli

I'm assuming it's because digital medicine isn't just about application of AI to drug development because that would fit in biotech.

I'm assuming this is because you also have hospital record keeping.

You have patient management during clinical trials and multiply.

Is that right?

Is that why it fits better in this bucket together as opposed to... You're absolutely right.

Right, so I think we're going to talk about this.

I'm going to bring this up now, as you saw in my list of questions that I sent you.

It's a bit further down, but I think since we're on the topic, we'll talk about it now.

And also the biotech.

These are the two areas I know most and best.

Medical devices is really not my space at all.

So let's just talk about this AI topic here.

We've just conducted, it took us a long time to get this organized, a 600 plus C-suite survey for AI, which is published today.

10 or 12 questions general across the 600 folks and companies from about 1,000 individuals upwards, employees.

And then we went and segmented the companies into 10 buckets, one of which was pharmaceuticals.

So we have about 50 respondents.

And we will come back to that.

I'm going to do a webinar of our own with my colleague with our findings from what they said about the impact of AI that they are looking at within their companies.

But one of the key themes that seems to keep coming up is that the U.S.

seems to have pretty much, let's put China aside now because they have a different strategy that they're pursuing with NVIDIA, with the chat GPT, with OpenAI, with Anthropic, etc.